0.2517

4.66% -0.0123

Cellectar Biosciences Inc (CLRB)

Overview News Price History Financials Discussions Forecast Stock Split

Cellectar Biosciences Inc stock is traded at $0.2517, with a volume of 193.68K. It is down -4.66% in the last 24 hours and up +0.04% over the past month. Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Previous Close:

$0.264

Open:

$0.265

24h Volume:

193.68K

Relative Volume:

0.21

Market Cap:

$11.69M

Revenue:

Net Income/Loss:

$-37.75M

P/E Ratio:

-0.0774

EPS:

-3.25

Net Cash Flow:

$-30.91M

1W Performance:

+1.04%

1M Performance:

+0.04%

6M Performance:

-83.66%

1Y Performance:

-91.72%

1-Day Range:

$0.248

$0.265

1-Week Range:

$0.241

$0.267

52-Week Range:

$0.224

$3.42

Cellectar Biosciences Inc Stock (CLRB) Company Profile

Name

Cellectar Biosciences Inc

Sector

Healthcare (1177)

Industry

Biotechnology (671)

Phone

(608) 441-8120

Address

100 CAMPUS DRIVE, FLORHAM PARK, NJ

Employee

Twitter

@CellectarBio

Next Earnings Date

2025-03-05

Latest SEC Filings

CLRB's Discussions on Twitter

Compare CLRB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLRB Cellectar Biosciences Inc	0.2537	11.61M	0	-37.75M	-30.91M	-3.25
ONC Beone Medicines Ltd Adr	246.59	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	443.52	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	80.52	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	491.05	64.44B	14.09B	4.50B	2.96B	39.28

Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-05-24	Resumed	Ladenburg Thalmann	Buy
Jul-01-20	Initiated	Oppenheimer	Outperform
Jan-21-20	Resumed	ROTH Capital	Buy
Sep-13-19	Initiated	ROTH Capital	Buy
Dec-21-16	Initiated	Ladenburg Thalmann	Buy

Cellectar Biosciences Inc Stock (CLRB) Latest News

May 22, 2025

Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance

May 22, 2025

May 21, 2025

CVM Stock Offering Priced Below Previous Closing Value | CVM Stock News - GuruFocus

May 21, 2025

Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World

May 21, 2025

May 17, 2025

Cellectar signals Q3 EMA decision for conditional iopofosine approval while advancing pipeline and exploring strategic alternatives - MSN

May 17, 2025

Analysts Update Their Estimates For Cellectar Biosciences Inc - Stocksregister

May 17, 2025

Roth Capital Brokers Increase Earnings Estimates for CLRB - Defense World

May 17, 2025

Cellectar Biosciences’ (CLRB) “Hold” Rating Reiterated at Maxim Group - Defense World

May 17, 2025

May 15, 2025

Cellectar Biosciences Earnings Call: Progress Amid Challenges - TipRanks

May 15, 2025

Cellectar Biosciences (CLRB) Downgraded to 'Hold' by Maxim Group - GuruFocus

May 15, 2025

StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World

May 15, 2025

May 14, 2025

Cellectar Biosciences (CLRB) Downgraded Amid Strategic Uncertain - GuruFocus

May 14, 2025

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025